Alzheimer's Disease Prevention Clinical Trial
Official title:
Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study/ 18F-AV-45-A14 - CLINICAL EVALUATION OF FLORBETAPIR F 18 (18F-AV-45) Sponsor of 18F-AV-45-A14: Avid Radiopharmaceuticals
Researchers are trying to determine if cognitively normal subjects undergoing a moderate aerobic exercise program will accumulate less amyloid-ß (Aβ) concentration in their brain than subjects undergoing a non-aerobic exercise program, and further evaluating the safety and imaging characteristics of florbetapir F 18, the radioactive drug that will allow us to image changes in the brain amyloid-ß (Aβ).
After screening assessments have been completed, subjects will be randomized into one of two
groups: aerobic exercise group and non-aerobic exercise group. All subjects will be trained
on the Physical Activity Scale for the Elderly (PASE), using the Body Media armband, and
exercise diary. Subjects will also complete an online food questionnaire.
Subjects assigned to the aerobic exercise group will work with an exercise trainer who will
provide individual training (six half hour sessions) until they are proficient at the use of
the equipment and understand goals. Subjects will return to Brooks Family YMCA at their
convenience, but at a minimum of four times per week. Subjects will complete the exercise
journal daily and the Physical Activity Scale for the Elderly (PASE) questionnaire on a
monthly basis.
Subjects assigned to the non-aerobic exercise group will attend supervised classes on toning
and stretching at a minimum of four times per week. Subjects will complete the exercise
journal daily and the Physical Activity Scale for the Elderly (PASE) questionnaire on a
monthly basis.
;